Does HRTX pay a dividend and is it safe?

Heron Therapeutics Inc. (HRTX) offers a 0% cash dividend yield ($0.00 annualized) and 1.8% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Stock Ratings / Health Care / HRTX / dividends

XLO (25) PLRX (34) TLPH (36) HYFT (45) ⌘ Pro Terminal →

Heron Therapeutics Inc. (HRTX) Dividend Safety Gauge & 10-Year DRIP Compounder

$0.30 +6.27% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.30

Heron Therapeutics Inc. (HRTX) carries a Roarable Rating of E (Strong Sell) with 34/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $52.7M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on HRTX Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is HRTX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Heron Therapeutics Inc. (NASDAQ: HRTX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $0.30 (+6.27% 1D, market cap $52.7M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 10/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, HRTX ranks #642 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does HRTX compare to XLO and PLRX in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), HRTX carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of 73.3%, and ROIC of -35.0%. By comparison, XLO (Xilio Therapeutics Inc.) holds a E grade (25/100 RQD, P/E N/A, ROIC -35.0%, cap $52.8M) and PLRX (Pliant Therapeutics Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $53.2M). Among the 5-stock peer group, HRTX leads on earnings multiple (N/A) while HRTX leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for HRTX?

▼

Per HRTX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000818033), Heron Therapeutics Inc. generated $154.9M in revenue (+7.4% YoY), -$20.0M in net income, and -$27.9M in free cash flow against $255.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $0.30 (+0.94%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (34/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-8.7% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-10% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for HRTX)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (34/100 Composite)

🔍 WHY HRTX SCORES 34/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+10/20 pts (29% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (24% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$0.42-14.3% Next Q

Q2 (-2Q)

Grade E$0.36-16.7% Next Q

Q3 (-1Q)

Grade E$0.30+0% Next Q

Current

Grade E$0.30-8.7% Hist 90D α

Trajectory: D (42) → E (34)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a HRTX Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While HRTX currently carries a cautious 34/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.33) and Max Pain ($0.32) forces dealer call-delta covering toward $1.66.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $HRTX• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “HRTX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 34%NO 66%Trade / Inspect Odds →

CASH DIVIDEND + BUYBACK YIELD

1.8% Total Yield

0% Cash ($0.00/yr) + 1.8% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (6.8% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $19,307

Est. Year-10 Shareholder Yield: $348/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$10.7K

Yr 1

$11.4K

Yr 2

$12.2K

Yr 3

$13.0K

Yr 4

$13.9K

Yr 5

$14.8K

Yr 6

$15.8K

Yr 7

$16.9K

Yr 8

$18.1K

Yr 9

$19.3K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring HRTX)

✓Walkthrough of HRTX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

HRTX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -75.41%🛡️ HOLDING TREND SUPPORT

2026-11-03O $0.30H $0.30L $0.28C $0.30VOL 1.43M

RES: $0.47SUP: $0.22SMA50: $0.33SMA200: $0.69

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

HRTX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 HRTX Butterfly Map → + Track HRTX →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

8.0%/yr Implied 5Y Growth

vs. +7.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on HRTX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for HRTX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for HRTX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (HRTX)

Health Care Rank #642 of 1015 ⚔️ XLO vs HRTX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (HRTX vs. XLO, PLRX, TLPH, HYFT)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Heron Therapeutics Inc. (HRTX) ranks #642 by composite RQD confidence (34/100, grade E) and #738 by equity capitalization ($52.7M). Within this direct 5-issuer industry benchmark cohort, HRTX leads on earnings valuation at N/A trailing P/E, while HRTX leads on capital efficiency and profitability with -35.0% ROIC and 73.3% gross margin. HYFT currently holds the highest overall quantitative score in the immediate peer group at 45/100 (D) compared with HRTX at 34/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
HRTX ACTIVE Heron Therapeutics Inc.	E	34/100	—	73.3%	-35.0%	+6.27%	$52.7M	Benchmark Subject
XLO Xilio Therapeutics Inc.	E	25/100	—	—	-35.0%	-0.50%	$52.8M	/xlo-vs-hrtx →
PLRX Pliant Therapeutics Inc.	E	34/100	—	—	-35.0%	-2.29%	$53.2M	/plrx-vs-hrtx →
TLPH Talphera Inc.	D-	36/100	—	—	-35.0%	-1.94%	$53.5M	/tlph-vs-hrtx →
HYFT MindWalk Holdings Corp.	D	45/100	—	—	—	-2.65%	$53.8M	/hyft-vs-hrtx →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000818033 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Heron Therapeutics Inc. (HRTX) reported GAAP revenue of $154.9M (+7.4% vs. FY2024 revenue of $144.3M , and -50.0% cumulative change since FY2023) , GAAP net income of -$20.0M, operating cash flow of -$27.6M, and free cash flow of -$27.9M (-15.2% YoY). On the balance sheet, HRTX closed FY2025 with $255.9M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$154.9M	-$20.0M	-$27.6M	-$27.9M	$255.9M	—
FY2024 (FY)	2024-12-31	$144.3M	-$14.0M	-$22.5M	-$24.2M	$233.1M	—
FY2023 (FY)	2023-12-31	$309.7M	-$111.0M	-$58.8M	-$58.8M	—	—

3. HRTX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is HRTX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does HRTX compare to XLO and PLRX in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for HRTX?

Where is HRTX trading relative to its 50-day, 200-day, and 52-week technical levels?

HRTX last traded at $0.30 (+6.27% on volume of 1,218,814 shares), positioning the stock -9.09% below its 50-day simple moving average ($0.33) and -56.52% below its 200-day simple moving average ($0.69). Across its 52-week range of $0.26 to $1.58, HRTX sits at the 3.0% percentile with a 14-day RSI of 37.6 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.34).

Direct Sub-Reports: HRTX RQD Cockpit HRTX 12M Forecast HRTX Earnings & Move HRTX Dividends & DRIP HRTX Insiders & 13F HRTX Whale Options HRTX Profit Sankey HRTX News & Why

ROARABLE RATING BRIEF • RQD 34/100 (E) ✓ SEC XBRL & RQD VERIFIED

HRTX — Heron Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Heron Therapeutics Inc. (HRTX) earns a live Roarable RQD composite score of 34/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $0.30 (+6.27% 1D, market capitalization $52.7M).

Fundamental Cash Engine (7/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of 73.3%, operating margin of -1.6%, and free cash flow yield of —.
Whale 13F & Options Flow (10/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (6/20) + Forensic Balance Sheet (8/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 2/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Heron Therapeutics Inc. Is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry,. Per the market data, the company reports a gross margin of 73.3%, which indicates the economics of its sales are high at the gross level before operating costs.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Heron Therapeutics Inc. (HRTX) reported $154.9M in annual revenue (up from $144.3M in FY2024, +7.4% YoY) and -$20.0M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($309.7M revenue, -$111.0M net income) through FY2025, HRTX scaled operating cash flow to -$27.6M and free cash flow to -$27.9M, backed by $255.9M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (E • RQD 34/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 10/20. With Fundamental Cash Engine at 7/20 and Institutional Whale Flow at 10/20, sustained execution supports upside toward the upper end of the $0.26 – $1.58 52-week range.
🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -1.6% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

No upstream or downstream dependencies, sector correlations, or proprietary signal links are recorded for HRTX. A prospective investor should therefore treat second-order ripple analysis as unsupported by the current dataset.

Key Question #1: Can HRTX sustain or expand its -1.6% operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $154.9M and free cash flow of -$27.9M, how will capital allocation balance growth reinvestment against $0 in total debt?
Key Question #3: How sensitive is HRTX's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

HRTX Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Heron Therapeutics Inc. (HRTX) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to HRTX Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance • 23h ago

Heron Therapeutics to Report Third Quarter 2026 Financial Results on Monday, November 9, 2026

Yahoo Finance report covering Heron Therapeutics Inc. (HRTX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE MarketBeat • 1d ago

Heron Therapeutics, Inc. (HRTX) - What Are Investment Firms Thinking About This Stock?

MarketBeat report covering Heron Therapeutics Inc. (HRTX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST kalkine.ca • 1d ago

Heron Therapeutics: Acute Care Growth Offset by Oncology Weakness and Financial Uncertainty

kalkine.ca report covering Heron Therapeutics Inc. (HRTX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE MarketBeat • 1d ago

Investors Buy High Volume of Put Options on Heron Therapeutics (NASDAQ:HRTX)

MarketBeat report covering Heron Therapeutics Inc. (HRTX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE ad-hoc-news.de • 1d ago

Heron Therapeutics stock heads toward November 9 results

ad-hoc-news.de report covering Heron Therapeutics Inc. (HRTX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE MarketBeat • 1d ago

Heron Therapeutics (HRTX) Expected to Release Earnings on Tuesday

MarketBeat report covering Heron Therapeutics Inc. (HRTX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST ad-hoc-news.de • 1d ago

MarketBeat estimates November 3 results for Heron Therapeutics stock

ad-hoc-news.de report covering Heron Therapeutics Inc. (HRTX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

HRTX Bull vs. Bear Conversation Board — What's Your Call at $0.30?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON HRTX 🐻 33% BEARISH CONVICTION

DE DeltaGamma_99 RQD DEBATE OPENER • Options Flow Specialist 🐂 BULLISH 🎯 Target: $0.35 (+25.0%)

📌 Pinned Debate

Revenue grew from $144.3M to $154.9M in FY 2025 while operating income improved from -$11.5M to -$2.5M, and institutional and options a

Long HRTX at $0.28 targeting $0.35. Revenue grew from $144.3M to $154.9M in FY 2025 while operating income improved from -$11.5M to -$2.5M, and institutional and options activity registers as the strongest RQD pillar at 11 / 20.. Institutional whale score is 10/20 and the risk/reward vs. the $0.26 52-week low is skewed heavily in favor of bulls.

SectorRotator 🐂 BULL

@MeanReversion_88 Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Biotechnology: Pharmaceutical Preparations. If gross margin (73.3%) holds, EPS grows into the multiple faster than bears think.

ME MeanReversion_88 RQD DEBATE OPENER • Quantitative Statistical Arb 🐻 BEARISH 🎯 Target: $0.23 (-17.9%)

Spot @ $0.28

Negative free cash flow of -$27.9M in FY 2025, ROIC of -35%, a Piotroski F-Score of 2 out of 9, and an insider conviction pillar at onl

Sitting on the sidelines or leaning short HRTX above $0.28. Negative free cash flow of -$27.9M in FY 2025, ROIC of -35%, a Piotroski F-Score of 2 out of 9, and an insider conviction pillar at only 3 / 20 weigh on the RQD score of 37.. Until Fundamental Cash Engine (7/20) and FCF yield (0.0%) inflect higher, upside is capped near $1.58.